Agnes M Rimando

Author:

Agnes M. Rimando

ISBN #:

0841238219

Author:

Agnes M. Rimando

ISBN #:

0841239339

Author:

Agnes M. Rimando

ISBN #:

0841239789

US Patent:

8133917, Mar 13, 2012

Filed:

Oct 25, 2010

Appl. No.:

12/911376

Inventors:

Agnes M. Rimando - Oxford MS, US
Dennis R. Feller - Oxford MS, US
Wallace H. Yokoyama - Berekley CA, US

Assignee:

The United States of America as represented by the Secretary of Agriculture - Washington DC
The University of Mississippi - University MS

International Classification:

A61K 31/075
A61K 38/00
A01N 65/00

US Classification:

514720, 514 74, 424732

Abstract:

Resveratrol, a stilbenoid antioxidant found in grapes, wine, peanuts and other berries, has been reported to have hypolipidemic properties. Resveratrol and its three analogs (pterostilbene, piceatannol and resveratrol trimethyl ether) were evaluated for their effects on the activation of the peroxisome proliferator-activated receptor alpha (PPARα) isoforms, a receptor shown to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPARα in H4IIEC3 cells. Pterostilbene demonstrated the highest induction of PPARα demonstrating increases of 7- and 9-14 fold relative to control. The maximal responses to pterostilbene are similar to those obtained with the hypolipidemic drug, ciprofibrate; that is, pterostilbene acts as a PPARα agonist, like that of the fibrate class, and is a more effective hypolipidemic agent than resveratrol.

US Patent:

8252845, Aug 28, 2012

Filed:

Feb 1, 2012

Appl. No.:

13/363959

Inventors:

Agnes M. Rimando - Oxford MS, US
Dennis R. Feller - Oxford MS, US
Wallace H. Yokoyama - Berekley CA, US

Assignee:

The United States of America, as represented by the Secretary of Agriculture - Washington DC
The University of Mississippi - University MS

International Classification:

A61K 31/075
A61K 38/00
A01N 65/00

US Classification:

514720, 514 74, 424732

Abstract:

Resveratrol has been reported to have hypolipidemic properties. We investigated whether resveratrol and its analogs: pterostilbene, piceatannol and resveratrol trimethyl ether, would activate the peroxisome proliferator-activated receptor alpha (PPARα) isoform. This nuclear receptor is proposed to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPARα in H4IIEC3 cells transfected with a luciferase gene reporter construct. Pterostilbene demonstrated the highest induction of PPARα; the maximal response to pterostilbene was similar to that obtained with the hypolipidemic drug, ciprofibrate.

US Patent:

8383890, Feb 26, 2013

Filed:

Dec 15, 2006

Appl. No.:

11/639709

Inventors:

Zhiqiang Pan - Oxford MS, US
Agnes M. Rimando - Oxford MS, US
Scott R. Baerson - Oxford MS, US

Assignee:

The United States of America, as represented by the Secretary of Agriculture - Washington DC

International Classification:

A01H 5/00
C12N 15/82
C07H 21/04

US Classification:

800298, 800281, 435419, 536 232

Abstract:

This invention relates to the fatty acid desaturase genes, designated SbDES2 and SbDES3, cloned from an expressed sequence tag (EST) database prepared from isolated root hairs from sorghum. Heterologous expression of the cDNAs in revealed that recombinant SbDES2 converted palmitoleic acid (16:1Δ) to hexadecadienoic acid (16:2Δ), and that recombinant SbDES3 was capable of converting hexadecadienoic acid into hexadecatrienoic acid (16:3Δ). Desaturase enzymes capable of performing desaturation reactions producing a terminal double bond have not previously been characterized in a plant system.

US Patent:

8426369, Apr 23, 2013

Filed:

Dec 7, 2007

Appl. No.:

12/518271

Inventors:

Agnes M. Rimando - Oxford MS, US
Nanjoo Suh - Bridgewater NJ, US
Cassia Suemi Mizuno - Oxford MS, US
Subhashini Reddy - Bridgewater NJ, US

Assignee:

Rutgers, The State University of New Jersey - New Brunswick NJ

International Classification:

A61K 31/70
A61K 31/185
C07H 1/00
C07C 39/10

US Classification:

514 23, 514 25, 514576, 536 111, 536 41, 568765

Abstract:

Stilbene compounds for the prevention and treatment of colon cancer or colon inflammation and methods of using same are provided.

US Patent:

20060057231, Mar 16, 2006

Filed:

Aug 18, 2005

Appl. No.:

11/207038

Inventors:

Agnes Rimando - Oxford MS, US
Dennis Feller - Oxford MS, US
Wallace Yokoyama - Berekley CA, US

International Classification:

A61K 36/45
A61K 36/87
A61K 31/704

US Classification:

424732000, 424766000, 514025000

Abstract:

Resveratrol, a stilbenoid antioxidant found in grapes, wine, peanuts and other berries, has been reported to have hypolipidemic properties. We investigated whether resveratrol and its three analogs (pterostilbene, piceatannol and resveratrol trimethyl ether) would activate the peroxisome proliferator-activated receptor alpha (PPARα) isoform. This nuclear receptor is proposed to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes were evaluated along with ciprofibrate (positive control) at 1, 10, 100, 300 μM concentrations, for the activation of endogenous PPARα in H4IIEC3 cells. Cells were transfected with a peroxisome proliferator response element-AB (rat fatty acyl CoA β-oxidase response element)—luciferase gene reporter construct. Of the four analogs, pterostilbene demonstrated the highest induction of PPARα showing 7- and 9-14 fold increases in luciferase activity at 100 and 300 μM, respectively, relative to control. The maximal luciferase activity responses to pterostilbene at 100 μM are similar to those obtained with the hypolipidemic drug, ciprofibrate. These results suggest that pterostilbene acts as a PPARα agonist, like that of the fibrate class, and may be a more effective hypolipidemic agent than resveratrol.

US Patent:

20090069444, Mar 12, 2009

Filed:

Jun 10, 2008

Appl. No.:

12/136341

Inventors:

James A. Joseph - Plymouth MA, US
Agnes M. Rimando - Oxford MS, US

Assignee:

The United States of America, as represented by th e Secretary of Agriculture - Washington DC

International Classification:

A61K 31/09
A61P 25/00

US Classification:

514719

Abstract:

Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight.

US Patent:

20110225676, Sep 15, 2011

Filed:

Mar 10, 2010

Appl. No.:

12/721206

Inventors:

Scott R. Baerson - Oxford MS, US
Zhiqiang Pan - Oxford MS, US
Agnes M. Rimando - Oxford MS, US
Franck E. Dayan - Oxford MS, US
Daniel Cook - Providence UT, US

International Classification:

A01H 1/00
C07H 21/02
C07H 21/04
C12N 15/74
C12N 5/10
A01H 11/00
A61K 31/711
C12N 9/00
C12P 1/00
A61P 43/00

US Classification:

800281, 536 231, 536 232, 4353201, 435419, 4352523, 43525411, 4352572, 800295, 800278, 514 44 A, 435183, 435 41

Abstract:

Sorghum is considered to be an allelopathic crop species, producing phytotoxins such as the lipid benzoquinone sorgoleone (2-hydroxy-5-methoxy-3-[(Z,Z)-8′,11′,14′-pentadecatriene]-p-benzoquinone) which likely accounts for much of its allelopathic properties. Prior investigations into the biosynthesis of sorgoleone have suggested the participation of one or more alkylresorcinol synthases (ARS), which are type III polyketide synthases (PKS) that produce 5-alkylresorcinols using medium to long-chain fatty acyl-CoA starter units via iterative condensations with malonyl-CoA. Current evidence suggests that sorgoleone biosynthesis occurs exclusively in root hair cells, involving the synthesis of a 5-pentadecatrienyl resorcinol intermediate derived from an unusual 16:3 fatty acyl-CoA starter unit. To characterize the enzymes responsible for the biosynthesis of this alkylresorcinol intermediate, a previously-described expressed sequence tag (EST) database prepared from isolated root hairs was first mined for all PKS-like sequences. Quantitative real-time RT-PCR analyses revealed that two of these sequences were preferentially expressed in root hairs, and recombinant enzyme studies demonstrated that both sequences (designated ARS1 and ARS2) encode ARS enzymes capable of accepting a variety of fatty acyl-CoA starter units. Furthermore, RNA interference (RNAi) experiments directed against ARS1 and ARS2 resulted in the generation of multiple independent transformant events exhibiting dramatically reduced sorgoleone levels. Thus, both ARS1 and ARS2 are likely to participate in the biosynthesis of sorgoleone in planta. The sequences of ARS1 and ARS2 were also used to identify several rice genes encoding ARSs, which are likely involved in the production of defense-related alkylresorcinols.

US Patent:

20120035272, Feb 9, 2012

Filed:

Aug 8, 2011

Appl. No.:

13/204891

Inventors:

James A. Joseph - Plymouth MA, US
Agnes M. Rimando - Oxford MS, US

Assignee:

The United States of America as represented by the Secretary of Agriculture - Washington DC

International Classification:

A61K 31/065
A61P 25/00

US Classification:

514733

Abstract:

Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight.